Paraoxonase activity in athletes with depleted iron stores and iron-deficient erythropoiesis

Clinical Biochemistry

Volumn 43, Issue 15, 2010, Pages 1225-1229

  Martinoviá, Jelena ^a   Kotur Stevuljeviá, Jelena ^b   Dopsaj, Violeta ^b,c   Dopsaj, Milivoj ^b   Stefanoviá, Aleksandra ^b   Kasum, Goran ^b  

^a Belgrade Clinical Centre   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Deficient erythropoiesis; Exercise; Ferritin; Free radicals; Haemoglobin; Iron deficiency; Lipid hydroperoxides; Oxidative stress; Paraoxonase; Pro oxidant antioxidant balance

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; FERRITIN; HEMOGLOBIN; LIPID HYDROPEROXIDE; PARAOXON; TRANSFERRIN;

ADULT; ANEMIA; ARTICLE; ATHLETE; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ERYTHROCYTE; ERYTHROPOIESIS; FEMALE; HUMAN; IRON DEFICIENCY; IRON DEPLETION; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ARYLDIALKYLPHOSPHATASE; ATHLETES; CASE-CONTROL STUDIES; ERYTHROPOIESIS; FEMALE; HEMODYNAMICS; HUMANS; IRON; MALE; OXIDATIVE STRESS; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 77956746774     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.07.024     Document Type: Article

References (32)

1. Brownlie T., Untermohlen V., Hinton P.S., Haas J.D. Tissue iron deficiency without anemia impairs adaption in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 2004, 79:437-443.
2. Dopsaj V., Sumarac Z., Novakovic N., Dopsaj M. Determination of parameters of iron status in evaluation of anemia in elite young Serbian water polo players. Serb J Sports Sci 2008, 2:91-100.
3. Chatard J.C., Mujika I., Guy C., Lacour J.R. Anaemia and iron deficiency in athletes. Practical recommendations for treatment. Sports Med 1999, 27:229-240.
4. Radomsk M.W., Sabiston B.H., Isoard P. Development of sports anemia in physically fit men after daily sustained submaximal exercise. Aviat Space Environ Med 1980, 51:41-45.
5. Shaskey D.J., Gren G.A. Sports hematology. Sports Med 2000, 29:27-38.
6. Di Santolo M., Stel G., Banfi G., Gonano F., Cauci S. Anemia and iron status in young fertile non-professional female athletes. Eur J Appl Physiol 2008, 102:703-709.
7. Sarnak M.J., Tighiouart H., Manjunath G., MacLeod B., Griffith J., Salem D., Levey A.S. Anaemia as a risk factor for cardiovascular disease in the atherosclerosis risk in communities (ARIC) study. J Am Coll Cardiol 2002, 40:27-33.
8. Blatter M.C., James R.W., Messmer S., Barja F., Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45: identity of K-45 with paraoxonase. Eur J Biochem 1993, 21:871-879.
9. Ng C.J., Shih D.M., Hama S.Y., Villa N., Navab M., Reddy S.T. The paraoxonase gene family and atherosclerosis. Free Radical Biol Med 2005, 38:153-163.
10. Adkins S., Gan K.N., Mody M., La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993, 52:598-608.
11. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993, 3:73-76.
12. Kotur-Stevuljevic J., Spasic S., Jelic-Ivanovic Z., Spasojevic-Kalimanovska V., Vujovic A., Stefanovic A., Memon L., Kalimanovska-Ostric D. PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients. Clin Biochem 2008, 41:1067-1073.
13. Mackness M.I., Arrol S., Mackness B., Durrington P.N. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet 1997, 349:851-852.
14. Antikainen M., Murtomäki S., Syvanne M., Pahlman R., Tahvanainen E., Jauhiainen M., et al. The Gln-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996, 98:833-835.
15. Ombres D., Pannitteri G., Montali A., Candeloro A., Seccareccia F., Campagna F., et al. The Gln-Arg 192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 1998, 18:1611-1616.
16. Aslan M., Kosecik M., Horoz M., Selek S., Celik H., Erel O. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Atherosclerosis 2007, 191:397-402.
17. McKenzie S. Clinical laboratory hematology 2004, 189-202. Prentice Hall, New Jersey, by Pearson education.
18. Suominen P., Punnonen K., Rajamäki A., Irjala K. Serum transferrin receptor and transferrin receptor-ferritin index identify healthy subjects with subclinical iron deficits. Blood 1998, 92:2934-2939.
19. Nielsen P., Nachtigall D. Iron supplementation in athletes. Sports Med 1998, 26:207-216.
20. WHO/UNICEF/UNU Iron deficiency Anaemia: Assessment, Prevention and Control. A Guide for Programme Managers 2001, World Health Organization, Geneva.
21. Banfi G., Dolci A. Preanalytical phase of sport biochemistry and hematology. J Sports Med Phys Fit 2003, 43:223-230.
22. Lippi G., Banfi G., Buttarello M., Ceriotti F., Daves M., Dolci A., et al. Recommendations for detection and management of unsuitable samples in clinical laboratories. Clin Chem Lab Med 2007, 45:728-736.
23. Richter R., Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999, 9:745-753.
24. Alamdari D.H., Paletas K., Pegiou T., Sarigianni M., Befani C., Koliakos G. A novel assay for the evaluation of the prooxidant-antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients. Clin Biochem 2007, 40:248-254.
25. Nourooz Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods. Enzymol. 1999, 300:58-62.
26. Ferre N., Camps J., Fernandez-Ballart J., Arija V., Murphy M.M., Ceruelo S., et al. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem 2003, 49:1491-1497.
27. Jacob A. The integrated antioxidant system. Nutr Res 1995, 15:755-766.
28. Cozzi A., Santambrogio P., Levi S., Arosio A. Iron detoxifying activity of ferritin: effects of H and L human apoferritins on lipid peroxidation in vitro. FEBS Lett 1990, 277:119-122.
29. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Rad Biol Med 1999, 26:892-904 et al.
30. Morales N.P., Cherlermchoung C., Fucharoen S., Chantharaksri U. Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of β- thalassemia/hemoglobin E patients. Clin Chem Lab Med 2007, 45:884-889.
31. Q192R phenotype, is a predictor of coronary artery disease in a middle-aged Serbian population. Clin Chem Lab Med 2006, 44:1206-1213.
32. Meroño T., Sorroche P., Gómez Rosso L.A., Casañas L., Boero L.E., Arbelbide J.A., Brites F.D. Proatherogenic disturbances in lipoprotein profile, associated enzymes and transfer proteins in women with iron deficiency anaemia. Clin Biochem 2010, 43:416-423.